The fall issue of Cancer Today explores treatment advances for people with multiple myeloma whose cancer has returned or stopped responding to treatment, including CAR T-cell therapies and bispecific antibodies. The issue also covers the expanding role of antibody-drug conjugates, a drug that can boost the effectiveness of chemotherapy for platinum-resistant epithelial ovarian cancer, activity-based support groups for cancer survivors, and more.
The post Cancer Today’s Fall 2026 Issue: Activity-based Groups for Survivors, Expanding Treatment Options in Multiple Myeloma, and More appeared first on American Association for Cancer Research (AACR).
Source: Oncology
